A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 93
- Registration Number
- NCT04940039
- Locations
- 🇷🇼
University Teaching Hospital of Butare(CHUB), Butare, Rwanda
🇷🇼Kibuye Referral Hospital, Kibuye, Rwanda
🇷🇼CARAES Ndera Neuro-Psychiatric Hospital, Kigali, Rwanda
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 676
- Registration Number
- NCT04338321
- Locations
- 🇦🇷
FunDaMos, Ciudad Autonoma de Buenos Aires, Argentina
🇦🇷Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷CEN Consultorios Especializados en Neurociencias, Cordoba, Argentina
A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 29
- Registration Number
- NCT03947814
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪APEX GmbH, Munchen, Germany
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Registration Number
- NCT03852160
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 880
- Registration Number
- NCT03818035
- Locations
- 🇩🇪
Universitatsklinikum Dusseldorf, Düsseldorf, Germany
🇫🇷Hopital Prive d'Antony, Antony, France
🇫🇷Centre Hospitalier d'Auxerre, Auxerre, France
A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 42
- Registration Number
- NCT03816631
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪APEX GmbH, Munchen, Germany
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 225
- Registration Number
- NCT03809325
- Locations
- 🇫🇷
Hopital la Colombiere, Montpellier, France
🇫🇷Hopital Sainte Musse, Toulon, France
🇭🇺Tolna Megyei Balassa Janos Korhaz, Szekszárd, Hungary
A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 18
- Registration Number
- NCT03768609
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)
- Conditions
- Respiratory Tract Infections
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 118
- Registration Number
- NCT03574532
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Würzburg, Germany
🇪🇸Hosp. Univ. de La Princesa, Madrid, Spain
A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol
- Conditions
- Healthy
- Interventions
- Drug: JNJ-55308942 High DoseDrug: JNJ-55308942 Low DoseDrug: Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 14
- Registration Number
- NCT03547024
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium